Takeda Pharmaceutical has entered a strategic collaboration with Hong Kong-based Insilico Medicine to utilize artificial intelligence in early-stage drug discovery across its Japanese pharmaceutical company. The agreement gives Takeda access to Insilico's Pharma.AI platform, which is designed to support biological target identification and validation.
The specifics of the partnership remain under wraps, with neither Takeda nor Insilico disclosing which therapeutic areas or disease targets will be covered by the collaboration. However, it is understood that the deal has a total value of $600 million.
Insilico Medicine's Pharma.AI platform uses AI to analyze large datasets and identify potential biological targets for drugs. The company's technology aims to accelerate the discovery process, enabling pharmaceutical companies to develop new treatments more efficiently. Takeda, as part of this collaboration, will gain access to Insilico's expertise in utilizing AI to drive its drug discovery efforts.